 "covid, coronavirus, vaccine, drug, pharma")
Two vital drugs to treat Covid-19 patients got the drug regulator's nod on Friday. While Glenmark Pharma got the Drug Controller General of India’s (DCGI’s) approval to launch oral antiviral favipiravir, Maharashtra Health Minister Rajesh Tope claimed Cipla and Hetero also received the nod for Gilead’s repurposed drug remdesivir.
Mumbai-based Glenmark Pharmaceuticals is conducting phase-III clinical trials to assess the drug’s efficacy on Covid-19 patients. The drug may be available as early as next week, claimed sources.
India had given nod to remdesivir some time back based on the clinical trial data presented by the company. Now, two Indian licensees — Hetero
